The number of parasitoids developed per host is one of the major factors that influences future adult body size and reproductive success. Here, we examined four external factors (host species, heritability, host population density, and presence of predators) that can affect the number of the gregarious parasitoid Anaphes flavipes (Förster, 1841) (Hymenoptera: Mymaridae) wasps developing in one host. The effect of host population density on the number of parasitoid offspring developed per host was confirmed, and for the first time, we also showed that the number of offspring per host is influenced by the presence of predators. Low host density and presence of predators increases the number of wasps developed in one host egg. However, a higher number of A. flavipes in one host reduces A. flavipes body size and hence its future individual fertility and fitness. Our results highlighted the importance of some external factors that distinctly affect the number of wasp offspring. Therefore, in this context, we suggest that in comparison to solitary parasitoids, the gregarious parasitoid A. flavipes can better respond to various external factors and can more flexibly change its population density.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465251 | PMC |
http://dx.doi.org/10.1038/s41598-019-42503-4 | DOI Listing |
Sci Rep
January 2025
School of Geography and Environment, Liaocheng University, Liaocheng, 252059, Shandong, China.
The complex topography of the mountain cities leads to uneven distribution of land resources. Currently, available studies mainly focuse on land use and landscape patterns (LU and LP) in plains or plateaus. Thus, it is necessary to carry out an analysis of the drivers of changes in LU and LP in mountain cities.
View Article and Find Full Text PDFJ AAPOS
January 2025
University of Health Sciences, Department of Ophthalmology, Başakşehir Cam and Sakura City Hospital, Istanbul, Turkey.
Purpose: To use swept-source optical coherence tomography angiography (SS-OCTA) to investigate the alterations in retinal vascular density (VD) in patients presenting with congenital unilateral trochlear nerve palsy.
Methods: The medical records of patients diagnosed with congenital unilateral trochlear nerve palsy and those of a healthy control group were reviewed retrospectively. Comprehensive ocular examinations and SS-OCTA imaging were conducted.
Objectives: Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality globally, influenced by a complex interplay of risk factors including lipid disorders and insulin resistance (IR). The triglyceride-glucose (TyG) index and the triglyceride to high-density lipoprotein cholesterol (TG/HDL) ratio have emerged as potential indicators for assessing cardiovascular risk. This study aimed to evaluate the predictive value of hypertriglyceridemia, the TyG index, and the TG/HDL ratio for mortality and CVD occurrence within an Iranian population.
View Article and Find Full Text PDFLancet Neurol
February 2025
Department of Neurology, International University of Health and Welfare, Narita, Japan.
Background: Evidence from preclinical studies suggests that IL-6 signalling has the potential to modulate immunopathogenic mechanisms upstream of autoantibody effector mechanisms in patients with generalised myasthenia gravis. We aimed to assess the safety and efficacy of satralizumab, a humanised monoclonal antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis.
Methods: LUMINESCE was a randomised, double-blind, placebo-controlled, multicentre, phase 3 study at 105 sites, including hospitals and clinics, globally.
Lancet Neurol
February 2025
Janssen Research & Development, a Johnson & Johnson Company, Titusville, NJ, USA.
Background: Given burdensome side-effects and long latency for efficacy with conventional agents, there is a continued need for generalised myasthenia gravis treatments that are safe and provide consistently sustained, long-term disease control. Nipocalimab, a neonatal Fc receptor blocker, was associated with dose-dependent reductions in total IgG and anti-acetylcholine receptor (AChR) antibodies and clinically meaningful improvements in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale in patients with generalised myasthenia gravis in a phase 2 study. We aimed to assess the safety and efficacy of nipocalimab in a phase 3 study.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!